ICICI Prudential Nifty Pharma Index Fund Analyst Review: NAV, Returns and Key Insights 2026

The ICICI Prudential Nifty Pharma Index Fund Direct Growth plan has returned 14.90% over the past year, reflecting conditions in its investment segment. With a NAV of Rs 19.07 and an AUM of Rs 113.44 crore, the fund continues to maintain investor interest. This analyst review covers performance history, expense ratio, associated risks, and investment suitability for 2026

Click Here – Get Mutual Fund Advisory

What Is the ICICI Prudential Nifty Pharma Index Fund?

The ICICI Prudential Nifty Pharma Index Fund is a passively managed index fund that replicates the performance of a specific benchmark by investing in the same securities in the same proportions as the index. Index funds offer transparent, rules-based investing at a typically lower cost than actively managed funds. The fund carries a Very High risk rating and delivers market-linked returns that closely track its benchmark, net of the expense ratio.

ICICI Prudential Nifty Pharma Index Fund NAV and AUM

The current NAV of the ICICI Prudential Nifty Pharma Index Fund Direct Growth plan is Rs 19.07. NAV closely tracks the underlying index value, adjusted for the expense ratio and any tracking error. Always verify the most recent NAV on the AMC website or a registered mutual fund platform before placing any transaction.

With an AUM of Rs 113.44 crore, the fund is relatively nimble. This can be advantageous for portfolio agility and the ability to take positions without significant market impact. Investors should track AUM trends alongside performance metrics when evaluating this fund.

ICICI Prudential Nifty Pharma Index Fund Returns: Performance Snapshot

Period	Returns
1 Month	9.14%
3 Months	5.67%
1 Year	14.90%
3 Years (Annualised)	25.00%
5 Years (Annualised)	Not Available

The ICICI Prudential Nifty Pharma Index Fund has returned 14.90% over the past year and 5.67% over three months, reflecting softer conditions in its investment segment. Investors evaluating this fund should compare returns against the benchmark and category peers, and ensure they have a sufficient time horizon to absorb any further periods of subdued performance before committing capital.

Expense Ratio and Cost Efficiency

The ICICI Prudential Nifty Pharma Index Fund Direct Growth plan carries an expense ratio of 0.32% per annum, a competitive figure for its fund category. A lower expense ratio means a larger proportion of gross returns is retained by the investor. Combined with the direct plan’s elimination of distributor commissions, this provides a strong cost-to-value proposition over a long investment horizon.

Who Should Invest in ICICI Prudential Nifty Pharma Index Fund?

The ICICI Prudential Nifty Pharma Index Fund is well suited for investors who prefer a low-cost, passive approach to equity market participation with a Very High risk appetite and a minimum 5 to 7-year horizon. The minimum SIP is Rs 1000 and minimum lumpsum is Rs 1000. Index funds appeal particularly to investors who want broad market exposure without the risk of active manager underperformance. Conservative and short-horizon investors should avoid this fund.

Key Risks to Consider

Tracking Error Risk: Index funds can deviate from benchmark performance due to the expense ratio, dividend reinvestment timing, and constituent rebalancing lags, creating a tracking error.

No Downside Protection: A passive fund replicates index losses as completely as it replicates index gains. There is no fund manager discretion to reduce exposure during broad market downturns.

Concentration Risk: Some indices are heavily weighted toward a few large companies or sectors. A significant fall in those concentrated positions can have an outsized negative impact on NAV.

Concentration Risk: Funds with a focused investment mandate are more vulnerable to segment-specific headwinds than broadly diversified equity schemes.

Download the Univest iOS App or Univest Android App to track this fund’s live NAV and manage your portfolio.

Conclusion

The ICICI Prudential Nifty Pharma Index Fund has delivered modest returns in a challenging environment, but its expense ratio of 0.32% and AUM of Rs 113.44 crore reflect a cost-efficient and investor-supported structure. Those already holding this fund should review the underlying investment thesis. New investors should ensure they have a sufficient horizon before committing capital. Consult a SEBI-registered investment advisor before any allocation change.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Frequently Asked Questions

What is the current NAV of ICICI Prudential Nifty Pharma Index Fund?

Ans. The current NAV of the ICICI Prudential Nifty Pharma Index Fund Direct Growth plan is Rs 19.07. NAV is updated each trading day and reflects the closing market value of the fund’s underlying holdings. Always verify the most recent NAV on the AMC website or a SEBI-registered mutual fund platform before transacting.

What are the returns of ICICI Prudential Nifty Pharma Index Fund?

Ans. The fund has delivered a 1-year return of 14.90% and a 3-month return of 5.67%. The 3-year annualised return is 25.00% and the 5-year annualised return is Not Available. Past performance does not guarantee future results and should be evaluated alongside the fund’s risk profile and benchmark comparison.

What is the expense ratio of ICICI Prudential Nifty Pharma Index Fund Direct Growth?

Ans. The expense ratio of the ICICI Prudential Nifty Pharma Index Fund Direct Growth plan is 0.32% per annum. The direct plan eliminates distributor commissions and is more cost-efficient than the regular plan. Investors should always opt for the direct plan to maximise long-term net returns through the compounding advantage of lower costs.

Is this fund suitable for conservative investors?

Ans. No. This fund carries a Very High risk rating due to full market replication with no downside protection. It is not suitable for conservative investors or those with short investment timelines. A minimum 5 to 7-year horizon and a high risk tolerance are required prerequisites. Consult a SEBI-registered investment advisor before investing.

What is the minimum SIP amount for this fund?

Ans. The minimum monthly SIP is Rs 1000 and the minimum lumpsum investment is Rs 1000. The low entry thresholds make the fund accessible across income levels. A regular SIP approach is recommended to average out entry costs over time, particularly given the high-volatility nature of this fund’s category.

What category and sub-category does this fund belong to?

Ans. This fund is a passively managed index fund tracking a specific benchmark index. It falls under the Index Fund sub-category and is available as a direct growth plan, which eliminates distributor commissions and typically offers superior net returns compared to the regular plan.